Conference appearance and recent stock momentum

AMN Healthcare Services (AMN) heads into its June 3 presentation at the 46th Annual William Blair Growth Stock Conference with fresh attention on its Q1 2026 earnings results and recent share price performance.

The company reported Q1 improvements in revenue, EBITDA, and earnings per share, which has drawn investor focus to the stock. For investors, the Chicago conference appearance offers another opportunity to hear from management following that update.

Recent Q1 earnings and the William Blair conference appearance come on the back of strong share price momentum, with a 30 day share price return of 43.84% and a year to date share price return of 102.45%. However, the 3 year total shareholder return has declined 71.43%.

If AMN's move has caught your attention, it can be useful to see how other healthcare related plays are trading, including companies applying AI in care delivery and staffing, via 40 healthcare AI stocks

With AMN trading at US$30.61, recent gains are strong and analyst targets sit slightly below the current price. However, fair value work still points to a small discount, so is this a fresh opportunity or is the market already pricing in future growth?

Most Popular Narrative: 57% Overvalued

Against the last close at $30.61, the most followed narrative pegs AMN Healthcare Services' fair value at $19.50, framing the recent rally as stretched.

While demographic pressures such as an aging U.S. population and persistently high demand for healthcare workforce flexibility are expected to drive long-term structural needs for AMN Healthcare's staffing services, recent sequential declines in demand for core offerings like Travel Nurse and lower volumes in academic medical centers signal that utilization and associated revenue may remain under pressure in the intermediate term. Although the company is investing heavily in technology and automation, including the AMN Passport app and AI-enabled solutions that could meaningfully enhance productivity and operating margins over time, pricing competition in Language Services and within core staffing segments is intense, and margin gains may be offset by rate pressure and slow recovery in volumes.

Want to see how this tension between pressured volumes and expected margin recovery translates into a single fair value number? The narrative leans on specific assumptions for revenue, profitability and the multiple the market might be willing to pay over time, and puts them through a discount rate that materially reshapes today’s implied price.

Result: Fair Value of $19.50 (OVERVALUED)

However, there are still clear swing factors, including reliance on large strike related contracts like Kaiser and ongoing pressure on Travel Nurse and Allied volumes, that could challenge this view.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Cash Flows Paint a Different Picture

The narrative driven fair value of $19.50 points to an overvalued stock, but the SWS DCF model currently suggests a different story. According to this model, AMN is trading about 3.2% below its estimated future cash flow value of $31.62. So which signal should carry more weight for you?

Next Steps

If this mix of optimism and caution feels hard to balance, do not wait for the crowd to decide for you. Stress test the upside and risks yourself by reviewing the 2 key rewards.

Looking for more investment ideas?

If AMN has sharpened your focus, do not stop here. Broaden your watchlist with stocked, research backed ideas that other investors may be overlooking.

• Target steady income potential by scanning companies that yield over 5% and appear built to sustain payouts through the 10 dividend fortresses.
• Hunt for quality at a discount by checking companies with strong cash flows and attractive valuations using the 46 high quality undervalued stocks.
• Lean toward resilience by focusing on companies with robust finances and low risk profiles through the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.